This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Angion Biomedica Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Angion Biomedica.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	19.8%
Revenue growth rate	-122.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	01 May 2023

Recent future growth updates

Recent updates

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Apr 27

Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely

Jan 05

We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully

Sep 11

Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price

Oct 05

We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely

Aug 18

Earnings and Revenue Growth Forecasts

NasdaqGS:ANGN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
12/31/2023	N/A	N/A	N/A	N/A	1
3/31/2023	1	-29	-31	-31	N/A
12/31/2022	2	-39	-38	-38	N/A
9/30/2022	28	-17	-48	-48	N/A
6/30/2022	30	-24	-55	-55	N/A
3/31/2022	30	-32	-56	-56	N/A
12/31/2021	28	-55	-53	-53	N/A
9/30/2021	3	-98	-18	-18	N/A
6/30/2021	2	-100	-25	-24	N/A
3/31/2021	2	-104	-27	-27	N/A
12/31/2020	3	-80	-23	-23	N/A
9/30/2020	3	-67	-48	-48	N/A
12/31/2019	1	-41	-25	-25	N/A
12/31/2018	4	-25	-8	-8	N/A
6/30/2014	6	0	N/A	1	N/A
3/31/2014	6	0	N/A	2	N/A
12/31/2013	7	1	N/A	2	N/A
12/31/2012	7	0	N/A	1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ANGN's forecast earnings growth is above the savings rate (2.1%).

Earnings vs Market: Insufficient data to determine if ANGN's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ANGN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ANGN is forecast to have no revenue next year.

High Growth Revenue: ANGN is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ANGN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/06/01 02:38
End of Day Share Price	2023/06/01 00:00
Earnings	2023/03/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Angion Biomedica Corp. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Raghuram Selvaraju	H.C. Wainwright & Co.
Justin Kim	Oppenheimer & Co. Inc.
Annabel Samimy	Stifel, Equities Research

This company is no longer active

Angion Biomedica Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$1.50

Price target increased to US$14.75

Price target decreased to US$15.00

Recent updates

Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. (NasdaqGS:ANGN) from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.47 loss in 1Q 2022)

Insufficient new directors

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Full year 2022 earnings released: US$1.29 loss per share (vs US$1.93 loss in FY 2021)

Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. (NasdaqGS:ANGN) in a reverse merger transaction.

Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely

Angion Biomedica Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Price target decreased to US$1.50

We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully

Second quarter 2022 earnings released: US$0.30 loss per share (vs US$0.57 loss in 2Q 2021)

Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M

Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022

Price target increased to US$14.75

Angion Biomedica Corp. Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease

Angion to discontinue phase 2 trial of ANG-3070 in patients with kidney disease

President recently bought US$101k worth of stock

First quarter 2022 earnings released: US$0.47 loss per share (vs US$1.57 loss in 1Q 2021)

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

Price target decreased to US$15.00

Full year 2021 earnings released: US$1.93 loss per share (vs US$5.43 loss in FY 2020)

We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth

Angion Biomedica: Selling At Cash Value

Interim Chief Financial Officer notifies of intention to sell stock

Angion Biomedica Corp. Provides ANG-3070 Program Update

President recently bought US$730k worth of stock

President recently bought US$106k worth of stock

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price

We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely

Angion Biomedica Corp Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

Angion Biomedica Corp. Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

Angion Biomedica Corp.(NasdaqGS:ANGN) dropped from Russell Microcap Value Index

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Angion Biomedica Corp. announced that it has received $25 million in funding from Vifor (International) AG

Angion Biomedica Corp. has completed an IPO in the amount of $80 million.